Waters Corporation
WAT
$410.70
+1.49%
Waters Corporation is a leading provider of analytical instruments, including liquid chromatography, mass spectrometry, and thermal analysis tools, serving the healthcare, pharmaceutical, and life sciences industries. The company is a market leader in these niche analytical technologies, known for its high-precision instruments and strong brand loyalty among scientists. In early 2026, Waters completed a transformative merger with BD's life science and diagnostics business, significantly expanding its diagnostics and discovery-related life science tools, which is now the central narrative driving investor attention. The market is debating the integration risks and growth potential of this expanded portfolio, as the company navigates a period of strategic transformation and revenue acceleration.…
WAT
Waters Corporation
$410.70
Investment Opinion: Should I buy WAT Today?
We rate Waters as a Hold, reflecting a balanced risk/reward profile. The consensus is 'Buy' with an average target of $436, implying 6.2% upside, but the recent net loss and margin compression warrant caution. The thesis is that the BD merger provides significant growth potential, but near-term profitability is uncertain, making the stock fairly valued at current levels.
Sign up to view all
WAT 12-Month Price Forecast
The AI assessment is neutral with medium confidence, reflecting the balanced risk/reward. The merger provides substantial growth potential, but the current financial performance is weak, with a net loss and margin compression. The valuation is not overly demanding on a P/S basis, but the forward P/E is high, indicating optimism about future earnings. The stance would be upgraded to bullish if margins recover above 55% and the company returns to profitability, or downgraded to bearish if integration issues lead to further losses. Key monitoring points include quarterly margin trends and the company's ability to achieve synergies.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Waters Corporation's 12-month outlook, with a consensus price target around $436.00 and implied upside of +6.2% versus the current price.
Average Target
$436.00
0 analysts
Implied Upside
+6.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$349 - $475
Analyst target range
Waters has coverage from 23 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.75 (where 1 is Strong Buy and 5 is Sell). The average price target is $436.00, implying a 6.2% upside from the current price of $410.70. The distribution includes 10 Buy ratings, 8 Hold ratings, and 5 Sell ratings, indicating a moderately bullish sentiment. The target price range is $349.00 to $475.00, with the high target suggesting a 15.7% upside, while the low target implies a -15.0% downside. The wide spread of $126.00 reflects significant uncertainty about the company's post-merger performance. Recent ratings from major firms like Goldman Sachs (Buy) and Morgan Stanley (Equal Weight) show a stable outlook, with no recent downgrades, indicating analysts are cautiously optimistic about the company's transformation.
Bulls vs Bears: WAT Investment Factors
Waters presents a compelling growth story driven by the transformative BD merger, which has nearly doubled revenue and expanded its market reach. However, the near-term financials are strained, with a net loss and significant margin compression, reflecting integration costs. The bull case rests on successful execution and margin recovery, while the bear case highlights the risk of prolonged profitability issues. Currently, the evidence slightly favors the bulls given the strong revenue growth, attractive P/S discount, and analyst optimism, but the margin trajectory is the key swing factor. If margins recover to pre-merger levels, the stock could re-rate higher; if not, the elevated forward P/E may prove unsustainable.
Bullish
- Transformative BD Merger: Q1 2026 revenue surged 91.5% YoY to $1.267B, driven by the BD life science and diagnostics acquisition, expanding Waters' TAM and adding high-growth diagnostics capabilities. This strategic shift positions the company for accelerated growth beyond its legacy chromatography franchise.
- Strong Price Momentum: The stock is up 41.4% over the past year, outperforming the S&P 500's 20.5% gain, and trades at 97.4% of its 52-week high of $421.74. This reflects investor confidence in the merger's long-term value creation and improving market sentiment.
- Attractive Valuation vs. Peers: At 7.14x P/S, Waters trades below the industry average of 8.5x, suggesting a potential discount. The forward P/E of 24.79x implies the market expects earnings to recover strongly, offering upside if integration delivers synergies.
- Analyst Consensus Buy: With 23 analysts, the consensus is 'Buy' (mean rating 1.75), and the average price target of $436 implies 6.2% upside. The high target of $475 suggests 15.7% upside, indicating analysts see further gains from current levels.
Bearish
- Q1 2026 Net Loss: Waters reported a net loss of -$72M in Q1 2026, with a net margin of -5.7%, a sharp reversal from the 24.2% margin in Q4 2025. This highlights significant integration costs and margin compression, raising concerns about near-term profitability.
- Margin Deterioration: Gross margin fell to 46.96% in Q1 2026 from 59.8% in Q4 2025, a 12.8 percentage point drop. Operating margin turned negative at -3.7%, indicating the merger is currently dilutive to profitability.
- High Valuation Multiples: Despite the recent loss, the forward P/E of 24.79x and EV/EBITDA of 23.23x are elevated, leaving little room for error. If earnings recovery disappoints, the stock could face multiple compression.
- Integration Execution Risk: The BD merger is complex, and integration risks are significant. The wide analyst target range ($349-$475) reflects uncertainty about the company's ability to achieve synergies and stabilize margins.
WAT Technical Analysis
Waters Corp is in a strong uptrend, with the stock price at $410.70, up 41.4% over the past year, significantly outperforming the S&P 500's 20.5% gain. The stock is trading near its 52-week high of $421.74, at 97.4% of the high, and 45.2% above its 52-week low of $282.77. This positioning near the highs indicates strong momentum, though it also suggests the stock may be overextended in the short term, with potential for a pullback.
Beta
1.18
1.18x market volatility
Max Drawdown
-31.3%
Largest decline past year
52-Week Range
$283-$422
Price range past year
Annual Return
+41.4%
Cumulative gain past year
| Period | WAT Return | S&P 500 |
|---|---|---|
| 1m | +10.8% | +3.6% |
| 3m | +20.0% | +2.7% |
| 6m | +23.2% | +11.4% |
| 1y | +41.4% | +18.7% |
| ytd | +7.5% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WAT Fundamental Analysis
Waters' revenue trajectory has been volatile, with the most recent quarter (Q1 2026) showing revenue of $1.267 billion, a 91.5% YoY increase, driven by the BD merger. However, this growth is not organic, and the company reported a net loss of -$72 million in Q1 2026, with a net margin of -5.7%, a sharp decline from the 24.2% net margin in Q4 2025. The gross margin in Q1 2026 was 46.96%, down from 59.8% in Q4 2025, indicating integration costs and margin pressure. The company's profitability has been inconsistent, with positive net income in the prior four quarters, but the recent loss raises concerns about the near-term earnings power.
Quarterly Revenue
$1.3B
2026-04
Revenue YoY Growth
+91.5%
YoY Comparison
Gross Margin
47.0%
Latest Quarter
Free Cash Flow
$263999000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WAT Overvalued?
Given the negative net income in the most recent quarter, the trailing P/E ratio is not meaningful, so I selected the P/S ratio as the primary valuation metric. The current P/S ratio is 7.14x, which is lower than the industry average of 8.5x, suggesting the stock is trading at a slight discount to its peers. However, the forward P/E of 24.79x implies the market expects earnings to recover strongly, which is optimistic given the recent loss. Historically, the P/S ratio has ranged from 19.7x to 32.5x over the past year, so the current 7.14x is well below the historical range, indicating a potential value opportunity if the company can execute its growth strategy.
PE
35.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 22x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are elevated due to the recent net loss and margin compression. In Q1 2026, Waters reported a net loss of -$72M and a negative operating margin of -3.7%, a stark contrast to the 24.2% net margin in Q4 2025. The gross margin dropped to 46.96% from 59.8%, indicating that the BD acquisition is currently dilutive. While the debt-to-equity ratio of 0.58 is manageable, the company's free cash flow of $264M TTM may be strained by integration costs and interest expenses, which rose to $48M in Q1. If margins do not recover as expected, the company could face cash flow challenges, especially with a high EV/EBITDA of 23.23x that leaves little room for operational underperformance.

